This study seeks to understand the safety of a gene editing therapy called CRISPR_SCD001 and if this treatment can help people with severe sickle cell disease get better.
Study doctors will use a ‘gene changing’ tool called CRISPR. The therapy changes the sickle gene mutation in a patient’s stem cells to a non-sickle gene that makes healthy hemoglobin. These gene-edited stem cells will be given back to the patient.
Patients will undergo high-dose chemotherapy to make room for the gene-edited stem cells to grow. They are then transplanted back into the patient.
This therapy has the potential to improve the health of individuals with sickle cell disease.
Read more2 United States of America sites
12-35 years
All
SCD type SS
Clinical
CRISPR_SCD001
1/2
A monetary stipend will be provided per visit to help offset housing and lodging costs. Please see “About the Study” details for information on Patient Support Resources.
Other inclusions may apply. Please visit this site and complete the eligibility survey to see if you are a good fit: https://ucsf.co1.qualtrics.com/jfe/form/SV_3JFOMmGHAjv6dJY
Other exclusions may apply. Please visit this site and complete the eligibility survey to see if you are a good fit: https://ucsf.co1.qualtrics.com/jfe/form/SV_3JFOMmGHAjv6dJY
Marci Moriarity, RN | |
510-428-3885 ext. 5396 | |
[email protected] |
Cyrus Bascon | |
510-428-3885 ext. 6953 | |
[email protected] |